Zenith Bank FY: 2017 Earnings: Resilient Performance… A Clear Case of Undervaluation

Mr. Peter Amangbo, Group MD/CEO, Zenith Bank Plc

Zenith Bank Plc released its FY: 2017 earnings result on the floor of the exchange on Monday and in line with expectation, Zenith’s performance was largely impressive.

Gross earnings surged 46.7% Y-o-Y to N745.2bn. The Bank’s Interest income rose 23.4% Y-o-Y from N384.6bn in FY: 2016 to N474.6bn in FY: 2017 following increased yield on loans and advances (from 10.9% in FY: 2016 to 11.8% in FY:2017) while Non-interest income surged 119.2% Y-o-Y to N270.6bn in FY:2017 from N123.4bn in the prior year, majorly due to the significant gains recorded from trading activities (especially Treasury Bills  and Derivatives trading). As noticed in 2017, more Banks seem to be focusing on trading activities to boost income given the attractive yield environment. This has been particularly true for Zenith which consistently recorded average quarterly trading income of N39.9bn between Q1:2017 to Q4:2017 from 2016 corresponding quarterly average of N7.1bn.

We believe this is an income line that has come to stay as the Bank takes advantage of opportunities in the market. Zenith was also able to maintain its drive to optimize cost as Cost to Income Ratio (CIR) moderated to 42.9% from 48.0% in FY: 2016 despite a 30.0% increase in OPEX (from N174.5bn to N226.9bn).

Accordingly, PAT advanced 37.2% Y-o-Y to N177.9bn from N129.7bn in the prior year while RoAE improved to 23.4% from 20.0% in the prior year. A final dividend of N2.45 (N0.25 paid for H1:2017) was proposed for the period, translating to an implied dividend yield of 7.9%. Our Compelling Investment Thesis for Zenith The resilience of Zenith is clearly demonstrated in its FY: 2017 performance and we have a positive outlook on future earnings in 2018 and beyond. In our view, the dividend yield (7.9%) on the stock is quite attractive given the current realities in the market and this presents a good opportunity for investors interested in dividend paying stocks. Furthermore, on a valuation basis, considering the pre-earnings announcement P/BV of 1.5x and current P/BV multiple of 1.2x, we believe the stock is currently undervalued and presents an attractive entry opportunity.

In a scenario in which the stock trades at the pre-earnings release P/BV, we envisage an implied price of N39.25 on ZENITH which presents an upside opportunity of 26.8% against a price of N31.00 (13/03/2018).

Against the backdrop of our expectation of positive performance in 2018 as well as the current attractive pricing on the stock, we believe it is Open Season on ZENITH! and investors should be on the hunt for the Stock.

spot_img
spot_img
spot_img
spot_img
spot_img

Hot this week

11 Poets Chase $100,000 Prize as The Nigeria Prize for Literature Unveils 2026 Poetry Longlist

Eleven outstanding poetry collections have emerged on the longlist...

CBN Gov, Yemi Cardoso, to Speak at Business Journal Fintech & Financial Inclusion Roundtable 2026

Mr. Olayemi Cardoso, Governor, Central Bank of Nigeria (CBN)...

Leadway Assurance Champions Insurance Adoption in Nigeria’s Creative Sector

Leadway Assurance, Nigeria’s leading insurance services provider and a...

Dangote Refinery Completes Landmark $2.5bn Private Equity Placement

Dangote Petroleum Refinery and Petrochemicals FZE (DPRP) has successfully...

NGX Chair: Africa Has a Unique Opportunity to Participate, Shape Global Financial System

The talking points by Dr. Umaru Kwairanga, Group Chairman,...

Topics

LASAA Commissions New offices to Boost Operations

L-R: The General Manager, Radio Lagos, Mr Olajide Lawal;...

Fidelity Bank Eyes Oversubscription to N127.1 bn Combined Offers

Against the background of groundswell of supports and enthusiasm...

Kenya, 1st Country to Launch ‘Novartis Access’ for Affordable Health

Novartis has announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. The Novartis portfolio is being offered to the Kenyan government, non-governmental organisations and other public-sector healthcare providers for USD 1 per treatment, per month.

NDIC CEO, Bello Hassan at 15th Islamic Finance Summit in Saudi Arabia

Dr. Ibrahim Alghofaily, MD, Arriyada Centre, Jeddah (Left) in...

Five Trends to Shape Nigerian ICT Space in 2020

Isa Pantami Minister of Communications & Digital Economy In a new...

Flydubai Announces 4th Year of Profitability, 25% Passenger Increase

Flydubai saw the number of passengers from across its...

NASENI EVC to Ensure Tech Transfer, Commercialisation of Innovation

Mr. Khalil Halilu The Executive Vice Chairman /CEO National Agency for...
spot_img

Related Articles

Popular Categories

spot_imgspot_img